The United Kingdom and the United States have concluded a important bilateral deal that will keep no duties on UK drug shipments entering the American market.
The Terms of the Pact
As part of the deal, the UK has committed to increase funding on pharmaceuticals through the National Health Service (NHS). This move ensures that duties on these vital exports will remain at zero for a duration of the next three years.
This agreement follows previous statements to dramatically increase tariffs on branded pharmaceutical products, with figures mentioned reaching double the cost.
"This deal between the Britain strengthens the global environment for innovative medicines and introduces long-overdue balance to American-British drug exports," an announcement noted.
Trade Impact
Drugs represent one of the UK's largest exports to the America, which is clearly the biggest market for large British pharmaceutical firms.
Statistics indicate that in the year leading up to September, the UK sold pharmaceutical products totaling £11.1bn to the US. This value accounted for 17.4% of total UK exports in that timeframe.
"This agreement safeguards jobs, stimulates capital expenditure and facilitates the UK to establish itself as a worldwide center for medical research," a government official stated.
Detailed British Pledges
The agreement includes several specific pledges from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a target to double overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The sum manufacturers must refund to the NHS to control costs will be capped at fifteen percent. In the past, repayments topped twenty percent.
Industry Background
The pact takes place against a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and approval rates.
The disagreement were intensified by claims that US consumers were paying several times more for the same drugs than patients in the Britain and the EU.
In recent months, several major drug company projects in the UK have been halted or cancelled, while major funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS had to spend more on treatments, noting that its expenditure on drugs had decreased as a share of its resources over the previous ten-year period.
